Fluconazole (all routes except local only) - Cumulative dose ≤ 150 mg

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Jick (92% received the single 150-mg dose preparation), 1999 Molgaard-Nielsen (150 mg), 2013 Berard (150 mg), 2019 31.03[0.89; 1.19]44,7845,229not evaluable Limb defects Jick (92% received the single 150-mg dose preparation), 1999 Molgaard-Nielsen (150 mg), 2013 Berard (150 mg), 2019 30.84[0.54; 1.30]12,4435,229not evaluable Congenital heart defects Jick (92% received the single 150-mg dose preparation), 1999 Molgaard-Nielsen (150 mg), 2013 21.29[0.96; 1.74]7,8854,316not evaluable Major congenital malformations Jick (92% received the single 150-mg dose preparation), 1999 Molgaard-Nielsen (150 mg), 2013 Berard (150 mg), 2019 31.03[0.89; 1.19]44,7845,229not evaluable Cleft lip with or without cleft palate Molgaard-Nielsen (150 mg), 2013 10.91[0.38; 2.18]1,2694,082not evaluable Cleft palate Molgaard-Nielsen (150 mg), 2013 10.90[0.22; 3.65]4994,082not evaluable Eye defects Berard (150 mg), 2019 11.03[0.33; 3.23]728913not evaluable Genital anomalies Berard (150 mg), 2019 11.70[0.84; 3.44]1,179913not evaluable Nervous system anomalies Berard (150 mg), 2019 11.18[0.49; 2.85]899913not evaluable Oro-facial clefts Jick (92% received the single 150-mg dose preparation), 1999 12.32[0.09; 57.20]1234not evaluable Polydactyly Jick (92% received the single 150-mg dose preparation), 1999 Molgaard-Nielsen (150 mg), 2013 20.71[0.16; 3.07]5994,316not evaluable Tetralogy of Fallot Molgaard-Nielsen (150 mg), 2013 13.18[1.18; 8.56]2914,082not evaluable Urinary malformations Berard (150 mg), 2019 11.31[0.73; 2.34]2,203913not evaluable Ventricular septal defect Molgaard-Nielsen (150 mg), 2013 11.02[0.60; 1.73]3,1864,082not evaluable Cardiac septal defects Berard (150 mg), 2019 10.98[0.58; 1.64]3,282913not evaluable Craniosynostosis Molgaard-Nielsen (150 mg), 2013 10.34[0.05; 2.38]7174,082not evaluable Diaphragmatic hernia Molgaard-Nielsen (150 mg), 2013 12.41[0.60; 9.71]2044,082not evaluable Digestive system anomalies Berard (150 mg), 2019 10.66[0.16; 2.70]625913not evaluable Hypoplastic left heart (HLH/HLHS) Molgaard-Nielsen (150 mg), 2013 12.28[0.57; 9.17]1864,082not evaluable Limb reduction defects (LRD) Molgaard-Nielsen (150 mg), 2013 11.26[0.40; 3.94]5564,082not evaluable Spina bifida Jick (92% received the single 150-mg dose preparation), 1999 13.49[0.32; 38.66]3234not evaluable Syndactyly Molgaard-Nielsen (150 mg), 2013 10.35[0.05; 2.48]6804,082not evaluable Intrauterine deaths Early intrauterine deaths (< 22 weeks) / Spontaneous abortions Inman (single 150mg dose), 1994 Berard (150 mg), 2019 21.09[0.23; 5.14]29,4961,759not evaluable Ectopic pregnancy 0----- Late intrauterine deaths (> 22 weeks) / Stillbirths Berard (150 mg), 2019 10.56[0.13; 2.41]71231not evaluable Therapeutic terminations of pregnancy Inman (single 150mg dose), 1994 11.43[0.66; 3.10]3858not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons